Bionoia Where life meets thought
Back to Journal
Journal Mucosa
Discovery

Molecular Pathways and Clinical Applications of Probiotics as Effective Supporters of Intestinal, Neurologic, and Cardiovascular Health: a Narrative Review

Read original paper
Editor's note
Probiotics may work at the mucosal interface through mechanistically plausible pathways—tight junction reinforcement, cytokine signaling, microbial metabolite production—that extend beyond the gut to influence neurologic and cardiovascular outcomes. This narrative synthesis consolidates scattered evidence but remains primarily mechanistic and observational; clinical effect sizes, particularly for neurologic claims, remain modest and inconsistent. Gastroenterologists and primary care physicians should find the intestinal data most actionable, while the brain-gut and cardiometabolic claims warrant skepticism pending larger, longer-duration trials.

Source: europepmc · Origin: CL · Nieto ÁVA, Diaz AH, Millán MH, Sagredo D, Gacitua JA. · The Journal of nutritional biochemistry · 2026-05-23

URL: https://pubmed.ncbi.nlm.nih.gov/42177952/

AI rationale (4/5, tier: unclassified): Directly addresses intestinal barrier integrity via tight-junction proteins and epithelial function; microbiome-host signalling mechanism.


<h4>Purpose of review</h4>This narrative review aims to synthesize current knowledge on the molecular mechanisms and clinical applications of probiotics across three major health domains: intestinal, neurologic, and cardiovascular.<h4>Recent findings</h4>•Intestinal health: Probiotics such as Lactobacillus rhamnosus GG and Bifidobacterium lactis BB-12 reinforce epithelial integrity via upregulation of tight-junction proteins (occludin, claudin-1), attenuate inflammation through cytokine modulation (↑IL-10, ↓TNF-α, IL-6), and restore eubiosis in conditions including IBS, constipation, and antibiotic-associated diarrhea. • Neurologic health: "Psychobiotic" strains (e.g., L. rhamnosus JB-1, B. longum 1714, L. helveticus R0052 + B. longum R0175) modulate neurotransmitter synthesis (GABA, serotonin), dampen HPA-axis hyperactivity, and reduce neuroinflammation, yielding improvements in anxiety, stress resilience, cognitive function, and slowing brain-atrophy progression in MCI and Alzheimer's disease. • Cardiovascular health: Meta-analyses of 30+ RCTs demonstrate that probiotic supplementation (notably L. acidophilus, L. plantarum, B. longum) lowers total and LDL cholesterol (-7 to -10 mg/dL) via bile-salt hydrolase activity, SCFA-mediated GPR signaling, direct cholesterol assimilation, and modestly reduces systolic (-2 to -4 mmHg) and diastolic blood pressure through anti-inflammatory pathways and improved endothelial function. • Safety: While generally safe in healthy populations, rare adverse events (bacteremia, D-lactic acidosis, horizontal gene transfer) have been reported in immunocompromised or critically ill individuals, underscoring the need for individualized risk-benefit assessments and rigorous adverse-event surveillance.<h4>Summary</h4>Probiotics exert strain-specific, multi-mechanistic benefits on gut barrier integrity, neuroendocrine signaling, and cardiometabolic regulation. To fully realize their therapeutic promise, future research must pursue large-scale, head-to-head clinical trials, integrate multi-omics and precision-design approaches, and establish standardized frameworks for safety monitoring and personalized formulation.

Published 2026-05-28 · Last kit-update 2026-05-28